Funding sources This study was supported by the University Medical Centre St Radboud Foundation, which received funding for the project from Pfizer, Janssen and AbbVie. Pfizer, Janssen and AbbVie played no role in the design and execution of the study; in data collection, data management, data analysis and interpretation of the data; or manuscript preparation, review and approval.
Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network†
Version of Record online: 19 MAY 2014
© 2014 British Association of Dermatologists
British Journal of Dermatology
Volume 170, Issue 5, pages 1158–1165, May 2014
How to Cite
van den Reek, J.M.P.A., van Lüumig, P.P.M., Otero, M.E., Zweegers, J., van de Kerkhof, P.C.M., Ossenkoppele, P.M., Njoo, M.D., Mommers, J.M., Koetsier, M.I.A., Arnold, W.P., Sybrandy-Fleuren, B.A.M., Kuijpers, A.L.A., Andriessen, M.P.M., Seyger, M.M.B., Kievit, W. and de Jong, E.M.G.J. (2014), Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network. British Journal of Dermatology, 170: 1158–1165. doi: 10.1111/bjd.12862
Conflicts of interest See Appendix.
Plain language summary available online
- Issue online: 19 MAY 2014
- Version of Record online: 19 MAY 2014
- Accepted manuscript online: 1 FEB 2014 06:29AM EST
- Manuscript Accepted: 27 JAN 2014
- University Medical Centre St Radboud Foundation
Vol. 170, Issue 6, 1382, Version of Record online: 19 JUN 2014
Although the effectiveness of biologics for psoriasis has been measured extensively with objective outcome measures, studies based on subjective, patient-reported outcome measures remain scarce.
To investigate satisfaction with medication, as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM) for biologics in daily practice psoriasis care in the first 6 months of treatment; and to identify possible differences in satisfaction with medication between patients experienced (biologics-experienced) and inexperienced (biologics-inexperienced) in the use of biologics.
TSQM baseline measurements were compared using measurements taken after 6 months, using the Wilcoxon signed-rank test for paired comparisons. Intention-to-treat with last observation carried forward (ITT with LOCF) and as-treated analyses were performed. The difference between biologics-experienced and biologics-inexperienced patients for TSQM was analysed using ITT with LOCF. At 6 months, outcomes for biologics-experienced and biologics-inexperienced patients were compared using the Mann–Whitney U-test.
One hundred and six patients were eligible for analysis, and treated with etanercept (n = 34), adalimumab (n = 49) or ustekinumab (n = 23). Fifty-four per cent of patients were biologics-inexperienced. A statistically significant improvement was seen in all domains of the TSQM (‘effectiveness’, ‘side-effects’, ‘convenience’ and ‘global satisfaction’) by comparison of months 3 or 6 with baseline (all P ≤ 0·02). After 6 months, biologics-inexperienced patients scored better on the ‘global satisfaction’ domain than biologics-experienced patients (P < 0·01).
We provide a prospective, longitudinal analysis of TSQM for biologics in daily practice psoriasis care. High satisfaction rates were achieved. The ‘effectiveness’ and ‘convenience’ domains showed the most room for improvement.